Shares of Nikola, Peabody Energy, Aqua Metals among others made the biggest move on Wednesday 24/12/2020 trading day. The highlighted stocks traded higher, and we have stated the reasons for the movement to help with insights on your investment decisions.
Nikola Corporation (NKLA)
Shares of Nikola traded higher despite cautious commentary from JP Morgan. The stock may be rebounding following last week’s dip on new that the company and Republic Services discontinued their collaboration on refuse truck development.
The stock soared 19.31% with its opening price at $13.85 to close at $16.40
Peabody Energy Corporation (BTU)
The over 39% upward movement of the stock was largely influenced by President Trump signing of $900 billion stimulus coronavirus relief bill on Sunday. The company announced an exchange offer and consent solicitation related to existing 6 percent senior secured notes due 2022.
Currently, the shares are at $2.40, from previous close of $1.72
Aqua Metals Inc (AQMS)
Shares of Aqua Metals traded higher after the company completed its V1.25L electrolyzer program on time and under budget. The company has The stock saw its share rise more than 29% on the trading day to continue its upward drive. This continues the recent uptrend for the company—as the stock is now up 132.31% in the past one-month time frame.
AQMS traded within $2.32 region in Thursday’s session to close Monday at $3.03
Chico’s FAS Inc (CHS)
The shares enjoyed a 27.52% upward movement despite not seeing any company-specific news from the session to justify price action. Movement may however be related to strength in retail names following the signing of a US Covid-19 retail bill.
Price started at $1.52 to close trading at $1.90
Myovant Sciences Ltd (MYOV)
The company’s shares traded higher following its announcement of collaboration with Pfizer in which the company will receive a $650 million upfront payment. It will also receive $200 million in milestone payments upon Food and Drug Administration approvals in women’s health. In addition, Myovant will receive tiered sales milestones upon reaching certain thresholds up to $2.5 billion in net sales for prostate cancer and women’s health disorders.
MYOV is a clinical-stage biopharmaceutical company that focuses on developing and commercializing therapies for the treatment of women’s health and endocrine diseases.
It’s price had closed at $22.75 on the previous day with its current price on 27.41 as at Monday’s closing.